GenSight Biologics SA 2022 IR
The report outlines GenSight Biologics' activities and financial results for the fiscal year 2022. The company focused on advancing its gene therapy pipeline, notably LUMEVOQ for Leber Hereditary Optic Neuropathy (LHON) and GS030 for Retinitis Pigmentosa. Key milestones included the successful production of LUMEVOQ engineering batches to validate corrective manufacturing actions and securing a thirty-five million euro credit facility from the European Investment Bank. GenSight also expanded its commercial readiness in Europe by establishing local affiliates and appointing country leads, despite withdrawing its EMA application for LUMEVOQ to address outstanding objections.
Company: GenSight Biologics SA
Sector: Professional & technical services
Country: France
Year: 2022
Type: IR
Pages: 324
Back to company
GenSight Biologics SA
Universal Registration Document
The report outlines GenSight Biologics' activities and financial results for the fiscal year 2022. The company focused on advancing its gene therapy pipeline, notably LUMEVOQ for Leber Hereditary Optic Neuropathy (LHON) and GS030 for Retinitis Pigmentosa. Key milestones included the successful production of LUMEVOQ engineering batches to validate corrective manufacturing actions and securing a thirty-five million euro credit facility from the European Investment Bank. GenSight also expanded its commercial readiness in Europe by establishing local affiliates and appointing country leads, despite withdrawing its EMA application for LUMEVOQ to address outstanding objections.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Workplace Fatalities
Employees